DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.
作者信息
Henry Brandy
出版信息
J Health Biomed Law. 2018 Sep;14:265-283.
Abstract
摘要
相似文献
1
DRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS.药品定价与丙型肝炎治疗可及性面临的挑战
J Health Biomed Law. 2018 Sep;14:265-283.
2
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?非洲的药品获取与丙型肝炎：分级定价和自愿许可能否确保普遍获取、健康公平与公正？
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.
3
The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition.支付方许可协议，或“网飞模式”，为丙型肝炎病毒治疗提供了普遍的治疗途径，降低了成本，并激励了创新和竞争。
Liver Int. 2022 Jul;42(7):1503-1516. doi: 10.1111/liv.15245. Epub 2022 Mar 26.
4
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.美国改善丙型肝炎治疗可及性的策略：州官员应对高药价、耻辱感及提升治疗能力问题
J Public Health Manag Pract. 2019 May/Jun;25(3):245-252. doi: 10.1097/PHH.0000000000000829.
5
Pharma Pricing & Market Access Europe 2016--Health Network Communications' Tenth Annual Conference (February 23-25, 2016--London, UK).2016年欧洲药品定价与市场准入——健康网络通信公司第十届年度会议（2016年2月23日至25日——英国伦敦）
Drugs Today (Barc). 2016 Mar;52(3):203-6. doi: 10.1358/dot.2016.52.3.2480580.
6
Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies.一次性给药细胞与基因治疗时代的定价与市场准入挑战。
Pharmaceut Med. 2022 Oct;36(5):265-274. doi: 10.1007/s40290-022-00443-x. Epub 2022 Aug 22.
7
The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.医药营销对市场准入、治疗覆盖范围、定价和社会福利的影响。
Health Econ. 2019 Aug;28(8):1035-1051. doi: 10.1002/hec.3903.
8
Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform.中国的药品定价改革：试点方法分析及改革的潜在影响
J Mark Access Health Policy. 2016 Mar 15;4. doi: 10.3402/jmahp.v4.30458. eCollection 2016.
9
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.定价与报销政策如何提高药品的可及性？从欧洲国家汲取的经验教训。
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
10
Market access and value-based pricing of digital health applications in Germany.德国数字健康应用的市场准入与基于价值的定价
Cost Eff Resour Alloc. 2022 Jun 13;20(1):25. doi: 10.1186/s12962-022-00359-y.
引用本文的文献
1
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.肯尼亚注射吸毒者丙型肝炎治疗的障碍与影响：一项定性研究
PLOS Glob Public Health. 2025 Jan 16;5(1):e0003284. doi: 10.1371/journal.pgph.0003284. eCollection 2025.
2
340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.340B 计划参与情况与联邦合格医疗中心的安全网参与情况。
JAMA Health Forum. 2024 Oct 4;5(10):e243360. doi: 10.1001/jamahealthforum.2024.3360.
3
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.丙型肝炎病毒的当代见解：全面综述
Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.
4
Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease.2010 年至 2019 年慢性丙型肝炎病毒相关结局的全球流行病学变化：肝硬化是丙型肝炎病毒相关疾病负担日益增加的原因。
Eur J Cancer Prev. 2024 Nov 1;33(6):512-524. doi: 10.1097/CEJ.0000000000000885. Epub 2024 Mar 22.
5
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌的潜在分子靶向治疗。
Curr Oncol. 2023 Jan 18;30(2):1363-1380. doi: 10.3390/curroncol30020105.
6
Value Insider Season 1 Episode 3: How Does Budget Impact and Affordability in Healthcare Work? (BI and Affordability) [Podcast].《价值洞察》第一季第三集：预算如何影响医疗保健的可及性与可负担性？（商业智能与可负担性）[播客]
Int J Gen Med. 2022 Oct 26;15:7879-7884. doi: 10.2147/IJGM.S390689. eCollection 2022.
7
Morin encapsulated chitosan nanoparticles (MCNPs) ameliorate arsenic induced liver damage through improvement of the antioxidant system and prevention of apoptosis and inflammation in mice.桑色素包裹的壳聚糖纳米粒（MCNPs）通过改善抗氧化系统以及预防小鼠细胞凋亡和炎症来减轻砷诱导的肝损伤。
Nanoscale Adv. 2022 May 17;4(13):2857-2872. doi: 10.1039/d2na00167e. eCollection 2022 Jun 28.
8
Factors Underlying Racial Disparity in Utilization of Hepatitis C-Viremic Kidneys in the United States.美国丙型肝炎病毒血症肾脏利用中的种族差异的相关因素。
J Racial Ethn Health Disparities. 2023 Oct;10(5):2185-2194. doi: 10.1007/s40615-022-01398-0. Epub 2022 Aug 23.
9
Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.决策规则在成本效益分析中的可负担性和价值：对卫生经济学家的调查。
Value Health. 2022 Jul;25(7):1141-1147. doi: 10.1016/j.jval.2021.11.1375. Epub 2022 Feb 24.
10
Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.鉴定可能有助于丙型肝炎病毒自发清除的抗体的线性表位特异性。
PLoS One. 2021 Aug 27;16(8):e0256816. doi: 10.1371/journal.pone.0256816. eCollection 2021.
本文引用的文献
1
Hepatitis C treatment: Back to the warehouse.丙型肝炎治疗：回归仓储式疗法。
Clin Liver Dis (Hoboken). 2015 Aug 24;6(2):27-29. doi: 10.1002/cld.490. eCollection 2015 Aug.
2
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.美国处方药价格居高不下：根源与改革前景。
JAMA. 2016;316(8):858-71. doi: 10.1001/jama.2016.11237.
3
New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison.新型慢性丙型肝炎病毒（HCV）全口服治疗：一项新的长期成本比较。
Cost Eff Resour Alloc. 2015 Oct 6;13:17. doi: 10.1186/s12962-015-0043-y. eCollection 2015.
4
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.索磷布韦/雷迪帕韦（哈瓦尼）用于真实世界队列中慢性丙型肝炎病毒感染的药物授权：丙型肝炎病毒治疗流程中的一个新障碍
PLoS One. 2015 Aug 27;10(8):e0135645. doi: 10.1371/journal.pone.0135645. eCollection 2015.
5
Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.获取昂贵的新型丙型肝炎药物：医学、金钱与倡导。
Clin Infect Dis. 2015 Dec 15;61(12):1825-30. doi: 10.1093/cid/civ677. Epub 2015 Aug 12.
6
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.基于索磷布韦的治疗方案在美国慢性丙型肝炎治疗中的成本效益
BMC Gastroenterol. 2015 Aug 5;15:98. doi: 10.1186/s12876-015-0320-4.
7
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.州医疗补助计划下新型丙型肝炎病毒治疗的获取受限。
Ann Intern Med. 2015 Aug 4;163(3):226-8. doi: 10.7326/M15-0320.
8
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.美国医疗补助计划对索磷布韦治疗丙型肝炎病毒感染的报销限制。
Ann Intern Med. 2015 Aug 4;163(3):215-23. doi: 10.7326/M15-0406.
9
National trends in prescription drug expenditures and projections for 2015.处方药支出的全国趋势及2015年预测。
Am J Health Syst Pharm. 2015 May 1;72(9):717-36. doi: 10.2146/ajhp140849.
10
Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.在一个充满歪曲的世界中寻找真相：索华迪案例中的谣言破除
Clin Ther. 2015 May 1;37(5):1092-112. doi: 10.1016/j.clinthera.2015.02.009. Epub 2015 Apr 4.
Zotero 插件